Aperio Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $1.84M | Buy |
29,681
+2,876
| +11% | +$178K | 0.01% | 1282 |
|
|
2020
Q3 | $1.59M | Sell |
26,805
-3,442
| -11% | -$205K | 0.01% | 1221 |
|
|
2020
Q2 | $2.11M | Sell |
30,247
-5,104
| -14% | -$356K | 0.01% | 1086 |
|
|
2020
Q1 | $1.6M | Buy |
35,351
+1,488
| +4% | +$67.5K | 0.01% | 1108 |
|
|
2019
Q4 | $2.2M | Buy |
33,863
+1,386
| +4% | +$90.2K | 0.01% | 1044 |
|
|
2019
Q3 | $2.02M | Sell |
32,477
-1,702
| -5% | -$106K | 0.01% | 1057 |
|
|
2019
Q2 | $2.43M | Buy |
34,179
+569
| +2% | +$40.5K | 0.01% | 971 |
|
|
2019
Q1 | $2.64M | Sell |
33,610
-1,457
| -4% | -$114K | 0.01% | 930 |
|
|
2018
Q4 | $2.97M | Sell |
35,067
-3,798
| -10% | -$322K | 0.02% | 829 |
|
|
2018
Q3 | $6.66M | Buy |
38,865
+637
| +2% | +$109K | 0.03% | 581 |
|
|
2018
Q2 | $4.94M | Sell |
38,228
-919
| -2% | -$119K | 0.02% | 671 |
|
|
2018
Q1 | $4.03M | Buy |
39,147
+707
| +2% | +$72.9K | 0.02% | 731 |
|
|
2017
Q4 | $3.28M | Buy |
38,440
+6,252
| +19% | +$534K | 0.02% | 800 |
|
|
2017
Q3 | $2.73M | Buy |
32,188
+954
| +3% | +$81K | 0.02% | 821 |
|
|
2017
Q2 | $2.37M | Buy |
31,234
+16,446
| +111% | +$1.25M | 0.01% | 846 |
|
|
2017
Q1 | $976K | Buy |
14,788
+3,573
| +32% | +$236K | 0.01% | 1181 |
|
|
2016
Q4 | $711K | Sell |
11,215
-1,835
| -14% | -$116K | 0.01% | 1311 |
|
|
2016
Q3 | $831K | Buy |
13,050
+2,215
| +20% | +$141K | 0.01% | 1191 |
|
|
2016
Q2 | $806K | Buy |
10,835
+1,485
| +16% | +$110K | 0.01% | 1169 |
|
|
2016
Q1 | $625K | Buy |
9,350
+2,901
| +45% | +$194K | 0.01% | 1258 |
|
|
2015
Q4 | $436K | Buy |
6,449
+1,098
| +21% | +$74.2K | ﹤0.01% | 1410 |
|
|
2015
Q3 | $286K | Buy |
5,351
+351
| +7% | +$18.8K | ﹤0.01% | 1585 |
|
|
2015
Q2 | $315K | Buy |
5,000
+625
| +14% | +$39.4K | ﹤0.01% | 1595 |
|
|
2015
Q1 | $210K | Buy |
+4,375
| New | +$210K | ﹤0.01% | 1805 |
|